These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32792446)

  • 21. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
    Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
    BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
    Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
    J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice.
    Aalbersberg EA; Geluk-Jonker MM; Young-Mylvaganan T; de Wit-van der Veen LJ; Stokkel MPM
    J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE.
    Soydal Ç; Peker A; Özkan E; Küçük ÖN; Kir MK
    Turk J Med Sci; 2016 Feb; 46(2):409-13. PubMed ID: 27511504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
    Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
    J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
    J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.
    Subramaniam RM; Bradshaw ML; Lewis K; Pinho D; Shah C; Walker RC
    Clin Nucl Med; 2018 Dec; 43(12):899-908. PubMed ID: 30394933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 68Ga DOTATATE PET/CT in a rare coexistence of pituitary macroadenoma and multiple paragangliomas.
    Parghane RV; Agrawal K; Mittal BR; Shukla J; Bhattacharya A; Mukherjee KK
    Clin Nucl Med; 2014 Jan; 39(1):91-3. PubMed ID: 24152628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
    Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous
    Maclean J; Fersht N; Sullivan K; Kayani I; Bomanji J; Dickson J; O'Meara C; Short S
    Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):448-458. PubMed ID: 28433399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection and localisation of primary prostate cancer using
    Kalapara AA; Nzenza T; Pan HYC; Ballok Z; Ramdave S; O'Sullivan R; Ryan A; Cherk M; Hofman MS; Konety BR; Lawrentschuk N; Bolton D; Murphy DG; Grummet JP; Frydenberg M
    BJU Int; 2020 Jul; 126(1):83-90. PubMed ID: 31260602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic utility of Gallium-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience.
    Varlamov E; Hinojosa-Amaya JM; Stack M; Fleseriu M
    Pituitary; 2019 Oct; 22(5):445-455. PubMed ID: 31236798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of hitherto unknown brain meningioma detected on
    Parghane RV; Talole S; Basu S
    World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.
    Łapińska G; Bryszewska M; Fijołek-Warszewska A; Kozłowicz-Gudzińska I; Ochman P; Sackiewicz-Słaby A
    Nucl Med Rev Cent East Eur; 2011; 14(1):16-20. PubMed ID: 21751167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.